Table 4. Primary endpoint; superiority subgroup analyses.

	All-cause mortality or new neurological event		Hazard ratio (95% CI)	p-value for superiority	p-value for heterogeneity *
	Dexamethasone	Placebo
LTA4H genotype - CT - CC	XX/XX XX/XX	XX/XX XX/XX	X.XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX	X.XX
Modified MRC grade - Grade I - Grade II - Grade III	XX/XX XX/XX XX/XX	XX/XX XX/XX XX/XX	X.XX (X.XX-X.XX) X.XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX X.XX	X.XX
TBM diagnosis - Definite - Probable - Possible	XX/XX XX/XX XX/XX	XX/XX XX/XX XX/XX	X.XX (X.XX-X.XX) X.XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX X.XX	X.XX
Drug resistance # - Rifampicin resistance - Isoniazid mono-resistance- - Susceptible to rifampicin and isoniazid	XX/XX XX/XX XX/XX	XX/XX XX/XX XX/XX	X.XX (X.XX-X.XX) .XX (X.XX-X.XX) X.XX (X.XX-X.XX)	X.XX X.XX X.XX	X.XX

* Heterogeneity is tested with a Cox regression model that includes an interaction between treatment effect and subgroup.

^# Rifampicin resistance: Tuberculosis resistant to rifampicin, with or without any other drug;

Isoniazid mono-resistance: Tuberculosis resistant to isoniazid, either alone or in combination with any drug except rifampicin; Susceptible to rifampicin and isoniazid: Tuberculosis susceptible to rifampicin and isoniazid, with or without resistance to other drugs.

XX/XX denotes the number of participants experiencing the event divided by the total number of participants in the treatment arm

CI=confidence interval. LTA4H= leukotriene A4 hydrolase. MRC=Medical Research Council.